Search

Your search keyword '"Cabriada, J.L."' showing total 27 results
Start Over Author "Cabriada, J.L."
27 results on '"Cabriada, J.L."'

1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

Author

Andrade, R.J., Lucena, M.I., Stephens, C., Cortés, M. García, Robles-Díaz, M., Ortega-Alonso, A., Pinazo, J., Muñoz, B. García, Alcántara, R., Hernández, A., Escaño, M.D. García, del Campo, E., Medina-Cáliz, I., Sanabria-Cabrera, J., González-Jiménez, A., Sanjuán-Jiménez, R., Cueto, A., Álvarez-Álvarez, I., Bonilla, E., Di Zeo, D., Niu, H., Villanueva, M., Papineau, A., Pérez, M. Jiménez, Grande, R. González, Ortega, S. López, Santaella, I., Ocaña, A., Palomino, P., Fernández, M.C., Peláez, G., Porcel, A., Casado, M., Sánchez, M. González, Romero-Gómez, M., Millán-Domínguez, R., Fombuena, B., Gallego, R., Ampuero, J., Campo, J.A. del, Calle-Sanz, R., Rojas, L., Rojas, A., Gómez, A. Gil, Vilar, E., Soriano, G., Guarner, C., Román, E.M., Manuitt, M.A. Quijada, Arbos, R.M. Antonijoan, Delgado, J. Sánchez, Gómez, M. Vergara, Hallal, H., Oltra, E. García, Arcos, J.C. Titos, Martínez, A. Pérez, Cobarro, C. Sánchez, Caparrós, J.M. Egea, Castiella, A., Zapata, E., Arenas, J., García, A. Gómez, Esandi, F.J., Blanco, S., Odriozola, P. Martínez, Crespo, J., Iruzubieta, P., Cabezas, J., Gallego, A. Giráldez, Rodríguez Seguel, E. del P., Cuaresma, M., Gallego, J. González, Jorquera, F., Campos, S. Sánchez, Otazua, P., de Juan Gómez, A., Salmerón, J., Gila, A., Quiles, R., González, J.M., Lorenzo, S., Prieto, M., Amiel, I. Conde, Berenguer, M., García-Eliz, M., Primo, J., Molés, J.R., Garayoa, A., Carrascosa, M., Domínguez, E. Gómez, Cuevas, L., Farré, M., Montané, E., Barriocanal, A.M., Arellano, A.L., Sanz, Y., Morillas, R.M., Sala, M., Ridaura, H. Masnou, Bruguera, M., Gines, P., Lens, S., García, J.C., Mariño, Z., Guerra, M. Hernández, Sanfiel, J.M. Moreno, Fernández del Campo, C. Boada, Tejedor, M., Ferrer, R. González, Fernández, C., Gil, M. Fernández, Montero, J.L., Mata, M. de la, Olmo, J. Fuentes, Bonilla, E.M. Fernández, Moreno, J.M., Martínez-Rodenas, P., Garrido, M., Oliva, C., Rendón, P., Samaniego, J. García, Madejón, A., Calleja, J.L., Porras, J.L. Martínez, Cabriada, J.L., Pérez-Moreno, J.M., Lara, C., Stephens, Camilla, Robles-Diaz, Mercedes, Medina-Caliz, Inmaculada, Garcia-Cortes, Miren, Ortega-Alonso, Aida, Sanabria-Cabrera, Judith, Gonzalez-Jimenez, Andres, Alvarez-Alvarez, Ismael, Slim, Mahmoud, Jimenez-Perez, Miguel, Gonzalez-Grande, Rocio, Fernández, M. Carmen, Casado, Marta, Soriano, German, Román, Eva, Hallal, Hacibe, Romero-Gomez, Manuel, Castiella, Agustin, Conde, Isabel, Prieto, Martin, Moreno-Planas, Jose Maria, Giraldez, Alvaro, Moreno-Sanfiel, J. Miguel, Kaplowitz, Neil, Lucena, M. Isabel, and Andrade, Raúl J.

Published
2021
Full Text
View/download PDF

3. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab

Author

Hernández-Breijo, B., Chaparro, M., Cano-Martínez, D., Guerra, I., Iborra, M., Cabriada, J.L., Bujanda, L., Taxonera, C., García-Sánchez, V., Marín-Jiménez, I., Barreiro-de Acosta, M., Vera, I., Martín-Arranz, M.D., Mesonero, F., Sempere, L., Gomollón, F., Hinojosa, J., Gisbert, J.P., and Guijarro, L.G.

Published
2016
Full Text
View/download PDF

6. Disease severity in familial cases of IBD

Author

Andreu, M., Márquez, L., Domènech, E., Gisbert, J.P., García, V., Marín-Jiménez, I., Peñalva, M., Gomollón, F., Calvet, X., Merino, O., Garcia-Planella, E., Vázquez-Romero, N., Esteve, M., Nos, P., Gutiérrez, A., Vera, I., Cabriada, J.L., Martín, M.D., Cañas-Ventura, A., and Panés, J.

Published
2014
Full Text
View/download PDF

7. P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study

Author

Ordas, I., Domenech, E., Aguas, M., Fernandez-Bañares, F., García, S., Peñalva, M., Muñoz, C., García-Sánchez, V., Lla, J., Jiménez, C.E., Merino, O., Gomolln, F., Piqueras, M., Vera, M., Márquez, L., De Castro, M., Gutiérrez, A., Cabriada, J.L., Alcaide, N., Calvet, X., Montoro, M.A., Arias, L., Panés, J., and Esteve, M.

Published
2017
Full Text
View/download PDF

10. DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients

Author

Taxonera, C., Ponferrada, A., Bermejo, F., Gisbert, J.P., Riestra, S., Saro, C., Cabriada, J.L., Barreiro-de Acosta, M., Barrio, J., Flores, E., Ferrer, I., Hernandez, A., Van Domselaar, M., Olivares, D., Alba, C., Fernández-Salazar, L., Merino, O., Botella, B., Ceballos, D., Moral, I., Peñate, M., and Algaba, A.

Published
2017
Full Text
View/download PDF

11. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

Author

Stephens, Camilla, primary, Robles-Diaz, Mercedes, additional, Medina-Caliz, Inmaculada, additional, Garcia-Cortes, Miren, additional, Ortega-Alonso, Aida, additional, Sanabria-Cabrera, Judith, additional, Gonzalez-Jimenez, Andres, additional, Alvarez-Alvarez, Ismael, additional, Slim, Mahmoud, additional, Jimenez-Perez, Miguel, additional, Gonzalez-Grande, Rocio, additional, Fernández, M. Carmen, additional, Casado, Marta, additional, Soriano, German, additional, Román, Eva, additional, Hallal, Hacibe, additional, Romero-Gomez, Manuel, additional, Castiella, Agustin, additional, Conde, Isabel, additional, Prieto, Martin, additional, Moreno-Planas, Jose Maria, additional, Giraldez, Alvaro, additional, Moreno-Sanfiel, J. Miguel, additional, Kaplowitz, Neil, additional, Lucena, M. Isabel, additional, Andrade, Raúl J., additional, Andrade, R.J., additional, Lucena, M.I., additional, Stephens, C., additional, Cortés, M. García, additional, Robles-Díaz, M., additional, Ortega-Alonso, A., additional, Pinazo, J., additional, Muñoz, B. García, additional, Alcántara, R., additional, Hernández, A., additional, Escaño, M.D. García, additional, del Campo, E., additional, Medina-Cáliz, I., additional, Sanabria-Cabrera, J., additional, González-Jiménez, A., additional, Sanjuán-Jiménez, R., additional, Cueto, A., additional, Álvarez-Álvarez, I., additional, Bonilla, E., additional, Di Zeo, D., additional, Niu, H., additional, Villanueva, M., additional, Papineau, A., additional, Pérez, M. Jiménez, additional, Grande, R. González, additional, Ortega, S. López, additional, Santaella, I., additional, Ocaña, A., additional, Palomino, P., additional, Fernández, M.C., additional, Peláez, G., additional, Porcel, A., additional, Casado, M., additional, Sánchez, M. González, additional, Romero-Gómez, M., additional, Millán-Domínguez, R., additional, Fombuena, B., additional, Gallego, R., additional, Ampuero, J., additional, Campo, J.A. del, additional, Calle-Sanz, R., additional, Rojas, L., additional, Rojas, A., additional, Gómez, A. Gil, additional, Vilar, E., additional, Soriano, G., additional, Guarner, C., additional, Román, E.M., additional, Manuitt, M.A. Quijada, additional, Arbos, R.M. Antonijoan, additional, Delgado, J. Sánchez, additional, Gómez, M. Vergara, additional, Hallal, H., additional, Oltra, E. García, additional, Arcos, J.C. Titos, additional, Martínez, A. Pérez, additional, Cobarro, C. Sánchez, additional, Caparrós, J.M. Egea, additional, Castiella, A., additional, Zapata, E., additional, Arenas, J., additional, García, A. Gómez, additional, Esandi, F.J., additional, Blanco, S., additional, Odriozola, P. Martínez, additional, Crespo, J., additional, Iruzubieta, P., additional, Cabezas, J., additional, Gallego, A. Giráldez, additional, Rodríguez Seguel, E. del P., additional, Cuaresma, M., additional, Gallego, J. González, additional, Jorquera, F., additional, Campos, S. Sánchez, additional, Otazua, P., additional, de Juan Gómez, A., additional, Salmerón, J., additional, Gila, A., additional, Quiles, R., additional, González, J.M., additional, Lorenzo, S., additional, Prieto, M., additional, Amiel, I. Conde, additional, Berenguer, M., additional, García-Eliz, M., additional, Primo, J., additional, Molés, J.R., additional, Garayoa, A., additional, Carrascosa, M., additional, Domínguez, E. Gómez, additional, Cuevas, L., additional, Farré, M., additional, Montané, E., additional, Barriocanal, A.M., additional, Arellano, A.L., additional, Sanz, Y., additional, Morillas, R.M., additional, Sala, M., additional, Ridaura, H. Masnou, additional, Bruguera, M., additional, Gines, P., additional, Lens, S., additional, García, J.C., additional, Mariño, Z., additional, Guerra, M. Hernández, additional, Sanfiel, J.M. Moreno, additional, Fernández del Campo, C. Boada, additional, Tejedor, M., additional, Ferrer, R. González, additional, Fernández, C., additional, Gil, M. Fernández, additional, Montero, J.L., additional, Mata, M. de la, additional, Olmo, J. Fuentes, additional, Bonilla, E.M. Fernández, additional, Moreno, J.M., additional, Martínez-Rodenas, P., additional, Garrido, M., additional, Oliva, C., additional, Rendón, P., additional, Samaniego, J. García, additional, Madejón, A., additional, Calleja, J.L., additional, Porras, J.L. Martínez, additional, Cabriada, J.L., additional, Pérez-Moreno, J.M., additional, and Lara, C., additional

Published
2021
Full Text
View/download PDF

14. Recomendaciones de vacunación en pacientes con enfermedad inflamatoria intestinal (EII)

Author

Rodríguez, C., Nantes, O., Gómez, M., Basterra, M., Cabriada, J.L., and Arín, A.

Subjects
Vacunas, Vaccines, Enfermedad inflamatoria intestinal, Inflammatory bowel disease, Immunosuppression, Inmunosupresión
Abstract

El concepto de enfermedad inflamatoria intestinal (EII) engloba tres entidades: la colitis ulcerosa (CU), la enfermedad de Crohn (EC) y la colitis inclasificable (CI). Estas enfermedades tienen en común el curso crónico y recidivante, alternando épocas de marcada actividad inflamatoria con otras quiescentes, en las que el paciente permanece asintomático. Durante muchos años la base del tratamiento, sobre todo en las fases agudas, se basó en el uso de corticoides. Sin embargo, a lo largo de las últimas décadas hemos asistido a avances importantes desde el punto de vista terapéutico. Así se estima que, a lo largo de la evolución de la enfermedad, el 80% de los pacientes van a precisar corticoides, el 40% inmunomoduladores (IMM) y hasta un 20% necesitará un fármaco biológico para el control de su enfermedad. Si bien todo ello se acompaña de una mejora en la calidad de vida, disminuyendo la necesidad de ingresos e intervenciones quirúrgicas, su uso implica también un incremento en el riesgo de sufrir infecciones, bien por gérmenes habituales en la comunidad o por gérmenes oportunistas. Las infecciones, además, son causa de morbimortalidad asociada a EII y algunas de ellas son prevenibles con vacunas, de ahí la importancia que los programas de vacunación están adquiriendo en este grupo de pacientes. Presentamos una revisión de la literatura al respecto y proponemos unas recomendaciones de vacunación para los pacientes diagnosticados de EII. The concept of inflammatory bowel disease (IBD) covers three entities: ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis (IC). These diseases have in common a chronic and relapsing course, alternating periods marked by inflammatory activity with other quiescent periods, in which the patient is asymptomatic. For many years treatment of the disease, especially in acute phases, was based on the use of corticoids. However, in recent decades we have witnessed significant advances from the therapeutic point of view. It is estimated that during the course of the disease's evolution 80% of patients will need corticoids, 40% immunomodulators (IMM), and as many as 20% will require a biological medicine to control their disease. While all of this is accompanied by an improvement in quality of life, less hospital admissions or surgical interventions, their use also involves an increase in the risk of suffering infections, either due to germs normally found in the community or opportunistic infections. Moreover, infections are a cause of morbidity and mortality associated with IBD and some of them can be prevented with vaccinations, hence the importance that vaccination programs are acquiring in this groups of patients. We present a review of the relevant literature and propose a vaccination protocol for patients diagnosed with IBD.

Published
2013

15. Partially covered self-expanding metal stent for unresectable malignant extrahepatic biliary obstruction: Results of a large prospective series

Author

Gómez-Oliva C., Guarner-Argente C., Concepción M., Jiménez F.J., Rodríguez S., Gonzalez-Huix F., Mugica F., Cabriada J.L., Rodríguez C., and Aguilar C.G.

Subjects
cannulation, iatrogenic disease, endoscopic retrograde cholangiopancreatography, Kaplan Meier method, bile duct obstruction, pancreatitis, middle aged, patient safety, acute cholecystitis, postoperative complication, Aged, 80 and over, evaluation, predictive value, cancer adjuvant therapy, article, clinical trial, methodology, cancer palliative therapy, biliary tract tumor, prosthesis failure, aged, cholangitis, female, tumor growth, Biliary Tract Neoplasms, priority journal, digestive system hemorrhage, obstructive jaundice, prospective study, endoscopic therapy, palliative therapy, bare metal stent, survival, cancer chemotherapy, male, pancreas cancer, cancer radiotherapy, human, gallbladder perforation, partially covered self expanding metal stent, stent migration, clinical effectiveness, digestive system perforation, extrahepatic bile duct obstruction, major clinical study, mortality, multicenter study, Cholangiopanc, inoperable cancer, treatment outcome, stent, stent patency
Abstract

Background: Endoscopic biliary stenting is a well-established palliative treatment in patients with unresectable malignant biliary strictures. Obstruction of uncovered selfexpanding metal stent (SEMS) due to tumor ingrowth is the most frequent complication. Partially covered SEMS might increase stent patency but could favor complications related to stent covering, such as pancreatitis, cholecystitis, and migration. The aim of this study was to evaluate the efficacy and safety of partially covered SEMS in patients with an unresectable malignant biliary stricture. Methods: Patients with malignant extrahepatic biliary obstruction treated endoscopically with partially covered SEMS were included in this multicenter, prospective, nonrandomized study. Results: One hundred ninety-nine patients were endoscopically treated with partially covered SEMS in 32 Spanish hospitals. Clinical success after deep cannulation was 96%. Early complications occurred in 4% (3 pancreatitis, 2 cholangitis, 1 hemorrhage, 1 perforation, and 1 cholecystitis). Late complications occurred in 19.5% (18 obstructions, 10 migrations, 6 cholangitis without obstruction, 3 acute cholecystitis, and 2 pancreatitis), with no tumor ingrowth in any case. Median stent patency was 138.9 ± 112.6 days. One-year actuarial probability of stent patency was 70% and that of nonmigration was 86%. Multivariate analysis showed adjuvant radio- or chemotherapy as the only independent predictive factor of stent patency and previous insertion of a biliary stent was the only predictive factor of migration. Conclusions: The partially covered SEMS was easily inserted, had a high clinical success rate, and prevented tumor ingrowth. The incidence of possible complications related to stent coverage, namely, migration, pancreatitis, and cholecystitis, was lower than in previously published series. © Springer Science+Business Media, LLC 2011.

Published
2012
Full Text
View/download PDF

18. P425 One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn's disease cohort

Author

Ginard, D., primary, Khorrami, S., additional, Marín, I., additional, Chaparro, M., additional, Aguas, M., additional, Martínez-González, J., additional, Cabriada, J.L., additional, García-Sánchez, V., additional, Villoria, A., additional, Gelabert, J., additional, Casellas, F., additional, Sansó, A., additional, Riera, J., additional, Hervías, D., additional, García, S., additional, García-Planella, E., additional, and Gisbert, J.P., additional

Published
2013
Full Text
View/download PDF

19. P365 Effectiveness of adalimumab in the treatment of perianal fistulas in patients with Crohn's disease naïve to anti-TNF: A multicenter study

Author

Castaño-Milla, C., primary, Chaparro, M., additional, Gismera, C. Saro, additional, Barreiro-de Acosta, M., additional, Garcia-Albert, A.M., additional, Bujanda, L., additional, Arranz, M.D. Martin, additional, Carpio, D., additional, Muñoz, F., additional, Marcos, N. Mancenido, additional, Garcia-Planella, E., additional, Piqueras, M., additional, Calvo, X. Calvet, additional, Cabriada, J.L., additional, Botella, B., additional, and Gisbert, J.P., additional

Published
2012
Full Text
View/download PDF

20. P407 Phenotypic concordance in familial inflammatory bowel disease (IBD)

Author

Cabré, E., primary, García-Sánchez, V., additional, Gutiérrez, A., additional, Panés, J., additional, Esteve, M., additional, Peñalva, M., additional, Nos, P., additional, Merino, O., additional, Ponferrada, A., additional, Gisbert, J.P., additional, García-Planella, E., additional, Ceña, G., additional, Cabriada, J.L., additional, and Montoro, M., additional

Published
2012
Full Text
View/download PDF

21. P252 Effectiveness and safety of ustekinumab as rescue therapy in multi-drug resistant Crohn's disease

Author

Ginard, D., primary, Khorrami, S., additional, Marín, I., additional, Chaparro, M., additional, Aguas, M., additional, Martínez-González, J., additional, Cabriada, J.L., additional, Sánchez, V. García, additional, Villoria, A., additional, Casellas, F., additional, Sansó, A., additional, Riera, J., additional, Hervías, D., additional, García, S., additional, García-Planella, E., additional, Muñoz, F., additional, and Gisbert, J.P., additional

Published
2012
Full Text
View/download PDF

22. LA DETERMINACIÓN SISTEMÁTICA DE LOS METABOLITOS DE LA AZATIOPRINA DURANTE EL SEGUIMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII) TRATADOS CON TIOPURÍNICOS NO ES ÚTIL: RESULTADOS FINALES DEL ESTUDIO METAZA

Author

González-Lama, Y., primary, McNicholl, A.G., additional, Bermejo, F., additional, López-Sanromán, A., additional, García, M.V., additional, Esteve, M., additional, Cabriada, J.L., additional, Pajares, R., additional, Casellas, F., additional, Merino, O., additional, Carpio, D., additional, Calvo, M., additional, Muñoz, C., additional, Benito, L.M., additional, Bufanda, L., additional, García-Hernández, F.J., additional, Ricart, E., additional, Ginard, D., additional, Velasco, M., additional, Carneros, J.A., additional, Manceñido, N., additional, Vera, M.I., additional, Algaba, A., additional, Froilan, C., additional, Abreu, L., additional, Maté, J., additional, Cara, C., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

23. FACTORES QUE PREDICEN UN CURSO DESFAVORABLE EN LA COLITIS ISQUÉMICA (C.I). RESULTADOS DEL GRUPO DE TRABAJO PARA EL ESTUDIO DE LA COLITIS ISQUÉMICA EN ESPAÑA (GTECIE)

Author

Montoro, M., primary, Santolaria, S., additional, Sánchez-Puértolas, B., additional, Bujanda, L., additional, Cosme, A., additional, Cabriada, J.L., additional, Durán, M., additional, Mata, L., additional, Santamaría, A., additional, Ceña, G., additional, Ponce, J., additional, Ponce, M., additional, Rodrigo, L., additional, Ortiz, J., additional, Muñoz, C., additional, Oceta, M., additional, Ginard, D., additional, López-Serrano, A., additional, Muñoz, M., additional, Castro, M., additional, Sans, M., additional, Campo, R., additional, Orive, V., additional, Loizate, A., additional, Titó, Ll., additional, Portabella, E., additional, Otazua, P., additional, Calvo, M., additional, Botella, M.T., additional, Mundi, J.L., additional, Quintero, E., additional, Nicolás, D., additional, Borda, F., additional, Martinez, B.P., additional, Gisbert, J., additional, Chaparro, M., additional, Jimenez Bernadó, A., additional, Gómez Camacho, F., additional, Cerezo, A., additional, and Casal Nuñez, E., additional

Published
2009
Full Text
View/download PDF

25. RESPUESTA A LARGO PLAZO DEL TRATAMIENTO CON INFLIXIMAB (IFX) EN LA ENFERMEDAD DE CROHN (EC) Y EFICACIA DE LA “INTENSIFICACIÓN” DE LA DOSIS EN LOS PACIENTES CON PÉRDIDA DE RESPUESTA

Author

Chaparro, M., primary, Panés, J., additional, García, V., additional, Mañosa, M., additional, Esteve, M., additional, Merino, O., additional, Cabriada, J.L., additional, Montoro, M.A., additional, Mendoza, J.L., additional, Bastida, G., additional, Gutierrez, A., additional, Gomollón, F., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results